Neuralstem (CUR) 3.41 $CUR
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 2.91 (+0.01), CYTX: 0.47 (unch), STEM: 1.09 (-0.01), ATHX: 2.12 (unch), CUR: 3.41 (+0.13), CELG: 115.88 (+0.16)
Neuralstem to Present at BIO CEO & Investor Conference 2015
PR Newswire - Tue Feb 03, 8:03AM CST
Neuralstem, Inc. (NYSE MKT: CUR) announced that Richard Garr, President and CEO, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, at 3:30 p.m. EST at the Waldorf Astoria in New York City.
CUR: 3.41 (+0.13)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Today's Review on Biotech Equities - Kite Pharma, Organovo Holdings, BioMarin Pharma, NephroGenex, and Neuralstem
PR Newswire - Fri Jan 09, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Kite Pharma Inc. (NASDAQ: KITE), Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), NephroGenex Inc. (NASDAQ: NRX), and Neuralstem Inc. (NYSE MKT: CUR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets surged on Thursday, January 08, 2015, as the Dow Jones Industrial Average finished at 17,907.87, up 1.84% and the NASDAQ Composite closed at 4,736.19, up 1.84%. The S&P 500 finished the session 1.79% higher at 2,062.14. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 819.86, up 1.72%, with the index gaining 11.71% in the previous three months. Register for your complimentary reports on these five stocks at:
BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), ONVO: 6.34 (+0.07), NRX: 6.67 (-0.14), CUR: 3.41 (+0.13)
Neuralstem To Present At Biotech Showcase 2015
PR Newswire - Tue Jan 06, 8:03AM CST
Neuralstem, Inc. (NYSE MKT: CUR) announced that the Company will present at the seventh annual Biotech Showcase in San Francisco on Tuesday, January 13, at 9:00 a.m. PST. Richard Garr, President and CEO, will present an overview on the company's clinical advancements of 2014 for both the cell therapy and small molecule drug discovery pipeline platforms. This will include the status of the company's lead cell therapy asset, NSI-566 for amyotrophic lateral sclerosis (ALS), and its lead neurogenic small molecule program, NSI-189, for the treatment of major depressive disorder.
CUR: 3.41 (+0.13)
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 37.22 (+0.27), LPCN: 5.91 (+0.40), EPRS: 7.67 (+0.67), DEPO: 18.38 (+0.20), ASPX: 65.76 (+2.76), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Hot Stock: Neuralstem, Shares Gain 5.7% (CUR)
Comtex SmarTrend(R) - Mon Jan 05, 10:06AM CST
Neuralstem (AMEX:CUR) is one of today's best performing low-priced stocks, up 5.7% to $2.97 on 1.8x average daily volume. Neuralstem has traded 877,000 shares thus far today, vs. average volume of 478,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's -1.2%) and outperformed the S&P 500 (5.7% to the S&P's -1.3%) during today's trading.
CUR: 3.41 (+0.13)
Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars
at The Street - Fri Jan 02, 10:02AM CST
Shares of Neuralstem (CUR) continue to rise in morning trading Friday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI), which touched a one-year high on Friday.
CUR: 3.41 (+0.13)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:14AM CST
KOOL: 0.88 (-0.14), BLDP: 2.66 (-0.26), PBR: 6.98 (+0.44), LNCO: 12.30 (+0.28), KITE: 62.59 (+0.82), NRX: 6.67 (-0.14), LINE: 12.94 (+0.40), PWRD: 18.95 (+0.02), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Neuralstem set for gap up at the open
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:07AM CST
CUR: 3.41 (+0.13)
One Reason Neuralstem (CUR) Stock is Rising Today
at The Street - Wed Dec 31, 11:42AM CST
Shares of stem cell therapy developer Neuralstem (CUR) were up on higher-than-average volume in afternoon trading Wednesday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI).
CUR: 3.41 (+0.13)
Neuralstem Up 5.4%, Shares Break Through Resistance (CUR)
Comtex SmarTrend(R) - Wed Dec 31, 11:35AM CST
Neuralstem (AMEX:CUR) is one of today's best performing low-priced stocks, up 5.4% to $2.74 on 3.9x average daily volume. Neuralstem has traded 1.7 million shares thus far today, vs. average volume of 428,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.2%) and outperformed the S&P 500 (5.4% to the S&P's -0.2%) during today's trading.
CUR: 3.41 (+0.13)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Investors look to Lighten Up on Shares of Neuralstem, Shares Down 5.8% (CUR)
Comtex SmarTrend(R) - Tue Dec 23, 12:42PM CST
Neuralstem (AMEX:CUR) is one of today's worst performing low-priced stocks, down 5.8% to $2.59 on 1.1x average daily volume. Neuralstem has traded 453,000 shares thus far today, vs. average volume of 431,000 shares per day. The stock has underperformed the Dow (-4.1% to the Dow's 0.6%) and underperformed the S&P 500 (-4.1% to the S&P's 0.3%) during today's trading.
CUR: 3.41 (+0.13)
Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 5.00 (-0.07), GEVA: 99.75 (-1.68), SGMO: 15.40 (+0.14), FOLD: 8.36 (-0.11), CUR: 3.41 (+0.13)
Cerebral Palsy - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdwf83/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Allergan - Acorda Therapeutics, Inc. - Neuralstem, Inc. - CHA Bio & Diostech Co., Ltd. - K-Stemcell Co., Ltd. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. For more information visit http://www.researchandmarkets.com/research/zd...bral_palsy
AGN: 229.49 (+1.87), ACOR: 36.14 (-0.51), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 391.66 (-0.45), KNMD: (), GSK: 47.94 (+1.99), BCLI: 3.86 (-0.02), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Could Pinky the “Super Mouse” End Alzheimer’s?
Ray Blanco - Daily Reckoning - Fri Dec 05, 2:18PM CST
This post Could Pinky the “Super Mouse” End Alzheimer’s? appeared first on Daily Reckoning . Biotech stocks delivered triple-digit returns throughout the ’80s and ’90s. But it’s been a decade since we’ve seen similar results....
CUR: 3.41 (+0.13)
Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), PRAN: 1.09 (-0.55), PTIE: 2.05 (+0.03), CUR: 3.41 (+0.13)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 2.91 (+0.01), CYTX: 0.47 (unch), STEM: 1.09 (-0.01), ATHX: 2.12 (unch), CUR: 3.41 (+0.13), CELG: 115.88 (+0.16)
Neuralstem to Present at BIO CEO & Investor Conference 2015
PR Newswire - Tue Feb 03, 8:03AM CST
Neuralstem, Inc. (NYSE MKT: CUR) announced that Richard Garr, President and CEO, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, at 3:30 p.m. EST at the Waldorf Astoria in New York City.
CUR: 3.41 (+0.13)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Today's Review on Biotech Equities - Kite Pharma, Organovo Holdings, BioMarin Pharma, NephroGenex, and Neuralstem
PR Newswire - Fri Jan 09, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Kite Pharma Inc. (NASDAQ: KITE), Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), NephroGenex Inc. (NASDAQ: NRX), and Neuralstem Inc. (NYSE MKT: CUR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets surged on Thursday, January 08, 2015, as the Dow Jones Industrial Average finished at 17,907.87, up 1.84% and the NASDAQ Composite closed at 4,736.19, up 1.84%. The S&P 500 finished the session 1.79% higher at 2,062.14. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 819.86, up 1.72%, with the index gaining 11.71% in the previous three months. Register for your complimentary reports on these five stocks at:
BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), ONVO: 6.34 (+0.07), NRX: 6.67 (-0.14), CUR: 3.41 (+0.13)
Neuralstem To Present At Biotech Showcase 2015
PR Newswire - Tue Jan 06, 8:03AM CST
Neuralstem, Inc. (NYSE MKT: CUR) announced that the Company will present at the seventh annual Biotech Showcase in San Francisco on Tuesday, January 13, at 9:00 a.m. PST. Richard Garr, President and CEO, will present an overview on the company's clinical advancements of 2014 for both the cell therapy and small molecule drug discovery pipeline platforms. This will include the status of the company's lead cell therapy asset, NSI-566 for amyotrophic lateral sclerosis (ALS), and its lead neurogenic small molecule program, NSI-189, for the treatment of major depressive disorder.
CUR: 3.41 (+0.13)
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 37.22 (+0.27), LPCN: 5.91 (+0.40), EPRS: 7.67 (+0.67), DEPO: 18.38 (+0.20), ASPX: 65.76 (+2.76), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Hot Stock: Neuralstem, Shares Gain 5.7% (CUR)
Comtex SmarTrend(R) - Mon Jan 05, 10:06AM CST
Neuralstem (AMEX:CUR) is one of today's best performing low-priced stocks, up 5.7% to $2.97 on 1.8x average daily volume. Neuralstem has traded 877,000 shares thus far today, vs. average volume of 478,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's -1.2%) and outperformed the S&P 500 (5.7% to the S&P's -1.3%) during today's trading.
CUR: 3.41 (+0.13)
Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars
at The Street - Fri Jan 02, 10:02AM CST
Shares of Neuralstem (CUR) continue to rise in morning trading Friday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI), which touched a one-year high on Friday.
CUR: 3.41 (+0.13)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:14AM CST
KOOL: 0.88 (-0.14), BLDP: 2.66 (-0.26), PBR: 6.98 (+0.44), LNCO: 12.30 (+0.28), KITE: 62.59 (+0.82), NRX: 6.67 (-0.14), LINE: 12.94 (+0.40), PWRD: 18.95 (+0.02), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Neuralstem set for gap up at the open
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:07AM CST
CUR: 3.41 (+0.13)
One Reason Neuralstem (CUR) Stock is Rising Today
at The Street - Wed Dec 31, 11:42AM CST
Shares of stem cell therapy developer Neuralstem (CUR) were up on higher-than-average volume in afternoon trading Wednesday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI).
CUR: 3.41 (+0.13)
Neuralstem Up 5.4%, Shares Break Through Resistance (CUR)
Comtex SmarTrend(R) - Wed Dec 31, 11:35AM CST
Neuralstem (AMEX:CUR) is one of today's best performing low-priced stocks, up 5.4% to $2.74 on 3.9x average daily volume. Neuralstem has traded 1.7 million shares thus far today, vs. average volume of 428,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.2%) and outperformed the S&P 500 (5.4% to the S&P's -0.2%) during today's trading.
CUR: 3.41 (+0.13)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Investors look to Lighten Up on Shares of Neuralstem, Shares Down 5.8% (CUR)
Comtex SmarTrend(R) - Tue Dec 23, 12:42PM CST
Neuralstem (AMEX:CUR) is one of today's worst performing low-priced stocks, down 5.8% to $2.59 on 1.1x average daily volume. Neuralstem has traded 453,000 shares thus far today, vs. average volume of 431,000 shares per day. The stock has underperformed the Dow (-4.1% to the Dow's 0.6%) and underperformed the S&P 500 (-4.1% to the S&P's 0.3%) during today's trading.
CUR: 3.41 (+0.13)
Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 5.00 (-0.07), GEVA: 99.75 (-1.68), SGMO: 15.40 (+0.14), FOLD: 8.36 (-0.11), CUR: 3.41 (+0.13)
Cerebral Palsy - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdwf83/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Allergan - Acorda Therapeutics, Inc. - Neuralstem, Inc. - CHA Bio & Diostech Co., Ltd. - K-Stemcell Co., Ltd. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. For more information visit http://www.researchandmarkets.com/research/zd...bral_palsy
AGN: 229.49 (+1.87), ACOR: 36.14 (-0.51), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 391.66 (-0.45), KNMD: (), GSK: 47.94 (+1.99), BCLI: 3.86 (-0.02), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Could Pinky the “Super Mouse” End Alzheimer’s?
Ray Blanco - Daily Reckoning - Fri Dec 05, 2:18PM CST
This post Could Pinky the “Super Mouse” End Alzheimer’s? appeared first on Daily Reckoning . Biotech stocks delivered triple-digit returns throughout the ’80s and ’90s. But it’s been a decade since we’ve seen similar results....
CUR: 3.41 (+0.13)
Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), PRAN: 1.09 (-0.55), PTIE: 2.05 (+0.03), CUR: 3.41 (+0.13)
